GlassScriptPhysician profile
Michael Ward Raybould
NPI 1083686273
$6,549.04
in general payments reported to CMS, 2019-2025
46 companies · $339 in 2025
The $339 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,431 · 2020: $367 · 2021: $542 · 2022: $1,246 · 2023: $1,483 · 2024: $1,141 · 2025: $339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,963.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,963.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $847.96 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $682.32 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $625.50 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $608.25 | 2019-2024 | Jardiance, Tradjenta, Synjardy |
| Pfizer INC. | $442.06 | 2019-2024 | |
| Amgen INC. | $432.79 | 2019-2025 | Otezla, Repatha, Evenity |
| Glaxosmithkline, LLC. | $404.50 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $371.90 | 2019-2025 | Rybelsus, Ozempic |
| Astellas Pharma US INC | $260.92 | 2019-2025 | Veozah |
| Merck Sharp & Dohme LLC | $186.98 | 2021-2024 | Belsomra, Gardasil 9, Gardasil |
| Novartis Pharmaceuticals Corporation | $171.57 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $164.01 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $117.29 | 2019-2022 | |
| Amarin Pharma, INC. | $101.30 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $93.13 | 2023-2025 | Gemtesa |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Raybould listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.